Ampio Pharmaceuticals (Ampio Pharmaceuticals) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ampio Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-2.31 Mil. Ampio Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Ampio Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Ampio Pharmaceuticals's current FCF Yield % is -3,015.49%.

The historical rank and industry rank for Ampio Pharmaceuticals's FCF Margin % or its related term are showing as below:

AMPE's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -144.01
* Ranked among companies with meaningful FCF Margin % only.

Ampio Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Ampio Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals FCF Margin % Chart

Ampio Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Ampio Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Ampio Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Ampio Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ampio Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's FCF Margin % falls into.

Ampio Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ampio Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.564	/	0
	=	%

Ampio Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2.309	/	0
	=	%

Ampio Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ampio Pharmaceuticals (Ampio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

373 Inverness Parkway, Suite 200, Englewood, CO, USA, 80112

Website

https://www.ampiopharma.com

Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the clinical development of Ampion and preclinical development. Its product candidate, Ampion, is in clinical trials and is being developed for the treatment of severe Osteoarthritis of the Knee, an intravenous treatment for COVID-19 patients, and an inhaled treatment for COVID-19-induced respiratory distress.

Executives

J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Michael A Martino	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens	director	300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes	director	640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka	officer: Chief Operating Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely	officer: CFO	4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E.	officer: Chief Financial Officer	373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow	officer: Chief Operating Officer	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso	director	C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles	director	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or	director, officer: Chief Scientific Officer	C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift	officer: Chief Regulatory Affairs	807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor	officer: Chief Financial Officer	5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111